Researchers have conducted one of the largest eye studies in the world to reveal new insights into retinal thickness, highlighting its potential in the early detection of diseases like type 2 diabetes ...
EyePoint's Duravyu meets primary endpoint in Phase 2 DME trial, showing potential to compete with Regeneron's Eylea and Roche ...
Long-term stabilizing of retinal exudation and fluid accumulation contributes to brolucizumab’s efficacy in managing wet age-related macular degeneration (AMD). Visual prognosis could be improved when ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback